All news

Eli Lilly lifts sales outlook as Zepbound surges

CNBC · RSS · · AI-summarised by FinFlash

Eli Lilly raised its sales outlook after third-quarter results showed another surge in its obesity drug Zepbound and diabetes treatment Mounjaro. The company's chief executive said there is room for "dramatic" expansion of the obesity market. Lilly is the largest U.S. healthcare company by market value.

Read original source

LLY company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.